Gene test may help breast cancer patients avoid major surgery

NCT ID NCT05666258

Completed Diagnosis Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a gene test called MammaPrint can help doctors decide which breast cancer patients need chemotherapy before surgery. The goal is to shrink tumors enough so that patients can have less invasive surgery, like a lumpectomy instead of a mastectomy. The study included 22 women with a specific type of breast cancer (HR+, HER2-).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MammaPrint gene expression profiling test
What this could lead to: If successful, this approach could help some breast cancer patients avoid mastectomy or full lymph node removal by identifying who benefits from chemo before surgery.
What could go wrong: This is a small, completed study with only 22 participants, so results may not apply to all patients. The gene test may not accurately predict who needs chemo, and some patients might still require more extensive surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Universitair Ziekenhuis Brussel

Jette, Brussels Capital, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.